Tempest Therapeutics (NASDAQ:TPST) Announces Earnings Results

Tempest Therapeutics (NASDAQ:TPST) posted its quarterly earnings results on Thursday. The company reported ($2.53) EPS for the quarter, missing the consensus estimate of ($0.28) by ($2.25), FiscalAI reports.

Tempest Therapeutics Trading Up 13.6%

TPST stock traded up $0.25 during midday trading on Thursday, hitting $2.09. The company had a trading volume of 252,668 shares, compared to its average volume of 176,203. Tempest Therapeutics has a 52 week low of $1.50 and a 52 week high of $12.23. The stock’s 50 day moving average price is $1.96 and its 200 day moving average price is $3.42. The stock has a market cap of $29.98 million, a price-to-earnings ratio of -0.31 and a beta of -1.75.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. Wall Street Zen upgraded shares of Tempest Therapeutics to a “hold” rating in a report on Saturday, April 18th. Zacks Research upgraded shares of Tempest Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, April 2nd. One analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy”.

Insiders Place Their Bets

In related news, CEO Matthew Angel acquired 231,482 shares of the stock in a transaction on Tuesday, March 24th. The stock was purchased at an average price of $2.16 per share, for a total transaction of $500,001.12. Following the completion of the transaction, the chief executive officer owned 231,482 shares of the company’s stock, valued at $500,001.12. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 6.28% of the company’s stock.

Hedge Funds Weigh In On Tempest Therapeutics

A hedge fund recently raised its stake in Tempest Therapeutics stock. Vanguard Group Inc. raised its position in Tempest Therapeutics, Inc. (NASDAQ:TPST) by 20.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 162,560 shares of the company’s stock after acquiring an additional 27,952 shares during the quarter. Vanguard Group Inc. owned approximately 3.66% of Tempest Therapeutics worth $1,671,000 at the end of the most recent quarter. 22.52% of the stock is currently owned by hedge funds and other institutional investors.

About Tempest Therapeutics

Tempest Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune‐mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator‐activated receptor alpha (PPARα) and salt‐inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.

The company’s lead candidate, TPST-1120, is a first‐in‐class PPARα antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells.